Announcements Trials
Browse Landscape

Phase

Phase 3 8Phase 2 4Phase 1 3Phase 2/3 2Phase NA 1Phase 1/2 1

Status

Completed 2Recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 3

Conditions

Sarcoma 27Breast Neoplasms 23Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Lymphoma, Large B-Cell, Diffuse 19Ovarian Neoplasms 14Neoplasms 14Lymphoma 12Burkitt Lymphoma 11Neoplasm Metastasis 10Recurrence 9Lymphoma, Non-Hodgkin 9Triple Negative Breast Neoplasms 8Neuroblastoma 7Fallopian Tube Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell, Peripheral 5Lymphoma, Large-Cell, Anaplastic 5Lymphoma, Follicular 5Lymphoma, B-Cell 5Leukemia 5Hodgkin Disease 5Unspecified Adult Solid Tumor, Protocol Specific 4Small Cell Lung Carcinoma 4Prostatic Neoplasms 4Multiple Myeloma 4Lymphoma, T-Cell 4Lung Neoplasms 4Liposarcoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia, Biphenotypic, Acute 4

Interventions

Doxorubicin 3pembrolizumab 2Radiotherapy 2ribociclib 1peposertib 1montanide ISA 51 1liposomal doxorubicin 1itacitinib 1futibatinib 1cixutumumab 1belinostat 1baricitinib 1avelumab 1Specimen Handling 1Radiation 1Nivolumab 1Magnetic Resonance Spectroscopy 1Ipilimumab 1Interleukin-2 1Ifosfamide 1INCB039110 1Histamine H2 Antagonists 1Fluorouracil 1Famotidine 1Erlotinib Hydrochloride 1Chemotherapy, Adjuvant 1Celecoxib 1Biopsy 1BO-112 1Angptl4 protein, mouse 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Histiocytoma, Malignant Fibrous × Doxorubicin × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT03009201 2023-08-16

Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery

OHSU Knight Cancer Institute

Phase 1 Completed
16 enrolled
Sarcoma

Fibrosarcoma, Hemangiosarcoma, Liposarcoma, Sarcoma, Disorders of Sex Development, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

NCT00720174 2016-05-17

Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma

National Cancer Institute (NCI)

Phase 1 Completed
30 enrolled
Sarcoma

Malignant mesenchymal tumor, Hemangiopericytoma, Malignant, Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡